Shire plc will gain a foothold in neonatology with its acquisition of Premacure AB, of Uppsala, Sweden. Premacure is developing a protein replacement therapy for the prevention of retinopathy of prematurity (ROP), a rare eye disease affecting about 14,000 to 16,000 preterm infants in the U.S. each year.